Health System Sees Success With E-Visits Via Patient Portal

Share this content:
Health System Sees Success With E-Visits Via Patient Portal
Health System Sees Success With E-Visits Via Patient Portal

WEDNESDAY, June 7, 2017 (HealthDay News) -- Patient portals can successfully offer access to physicians without office visits, according to a report published online May 30 by the American Medical Association.

Novant's new patient portal, MyNovant, has more than 720,000 users and allows patients to message their clinician, request prescription renewals, schedule appointments, and download their medical record. New patients can schedule appointments, and patients can also schedule time for an urgent-care visit. In addition, the e-visit feature has been launched, with 16,500 e-visits made so far.

Symptoms that qualify for an e-visit include sinus problems, red eye, diarrhea, cough, vaginal discharge, urinary issues, and back pain, as well as pediatric ringworm, pediatric swimmer's ear, and pediatric lice. Patients must answer all questions presented, and the information goes to the physician's nurse pool. If the nurse decides that the request is a good candidate for an e-visit, the information goes through to a physician. The patient receives a response within four hours of submitting their request. The fee for an e-visit is $30 for patients whose insurance companies won't cover it.

"Feedback on the e-visit has been positive, with 95 percent or more of patients rating other aspects of the e-visit as 'good' or 'very good,' including timeliness of response, likelihood of recommending, receiving the right information for the treatment, ease of initiating an e-visit, and needs being taken care of through the e-visit," according to the report.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths